特发性多中心型Castleman病的新见解与治疗进展
综述特发性多中心型Castleman病(iMCD)的病因、诊断与治疗进展,指出IL-6抑制剂司妥昔单抗基于34%持久缓解率于2014年获美国FDA批准,共识指南推荐其为一线治疗,但部分患者IL-6水平正常且存在替代驱动因子,司妥昔单抗难治患者仍需进一步研究。
要点
- iMCD诊断依据 clinicopathological 标准,分为TAFRO亚型与NOS亚型。
- 司妥昔单抗基于34%持久缓解率获FDA批准,共识指南推荐为一线治疗。
- 部分iMCD患者IL-6水平正常,存在替代驱动细胞因子和候选治疗靶点。
核心结论
- 尽管取得进展,iMCD仍认识不足,需进一步阐明病因、发病机制和治疗方法,尤其针对司妥昔单抗难治患者。
研究设计与样本
- 本文为综述,总结iMCD诊断、病因发病机制及治疗进展。
主要发现
- 失控的HHV-8感染导致约50%的MCD病例,其余HHV-8阴性/特发性MCD病因未知。
- clinicopathological分析为首个诊断标准提供证据基础,并揭示TAFRO和NOS两种临床亚型,全球可见。
- 司妥昔单抗基于34%持久缓解率于2014年获美国FDA批准,成为首个iMCD治疗药物。
- 近期细胞因子和蛋白质组学分析显示许多iMCD患者IL-6水平正常,并发现潜在替代驱动细胞因子。
- RNA测序未发现与iMCD病理相关的新病毒、HHV-8或其他病毒。
关键数值与推荐
- 共识指南推荐司妥昔单抗作为一线治疗。
临床怎么用
- 共识指南推荐司妥昔单抗作为iMCD一线治疗。
局限性
- 对iMCD涉及的病因、细胞类型和信号通路了解有限,阻碍了治疗开发并导致患者预后 historically 较差。
- 尽管取得进展,iMCD仍认识不足。
- 需进一步努力阐明病因、发病机制和治疗方法,尤其针对司妥昔单抗难治患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Castleman disease (CD) describes a heterogeneous group of hematologic disorders that share characteristic lymph node histopathology. Patients of all ages present with either a solitary enlarged lymph node (unicentric CD) or multicentric lymphadenopathy (MCD) with systemic inflammation, cytopenias, and life-threatening multiple organ dysfunction resulting from a cytokine storm often driven by interleukin 6 (IL-6). Uncontrolled human herpesvirus-8 (HHV-8) infection causes approximately 50% of MCD cases, whereas the etiology is unknown in the remaining HHV-8-negative/idiopathic MCD cases (iMCD). The limited understanding of etiology, cell types, and signaling pathways involved in iMCD has slowed development of treatments and contributed to historically poor patient outcomes. Here, recent progress for diagnosing iMCD, characterizing etio-pathogenesis, and advancing treatments are reviewed. Several clinicopathological analyses provided the evidence base for the first-ever diagnostic criteria and revealed distinct clinical subtypes: thrombocytopenia, anasarca, fever, reticulin fibrosis/renal dysfunction, organomegaly (iMCD-TAFRO) or iMCD-not otherwise specified (iMCD-NOS), which are both observed all over the world. In 2014, the anti-IL-6 therapy siltuximab became the first iMCD treatment approved by the US Food and Drug Administration, on the basis of a 34% durable response rate; consensus guidelines recommend it as front-line therapy. Recent cytokine and proteomic profiling has revealed normal IL-6 levels in many patients with iMCD and potential alternative driver cytokines. Candidate novel genomic alterations, dysregulated cell types, and signaling pathways have also been identified as candidate therapeutic targets. RNA sequencing for viral transcripts did not reveal novel viruses, HHV-8, or other viruses pathologically associated with iMCD. Despite progress, iMCD remains poorly understood. Further efforts to elucidate etiology, pathogenesis, and treatment approaches, particularly for siltuximab-refractory patients, are needed.
引用
- Fajgenbaum DC. Novel insights and therapeutic approaches in idiopathic multicentric Castleman disease. Blood. 2018. PMID: 30487129. doi:10.1182/blood-2018-05-848671
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。